Publications by authors named "F Dreyfus"
Article Synopsis
- Erythropoiesis-stimulating agents are the first-line treatment for anemia in patients with lower-risk myelodysplastic syndrome, with a study analyzing their effectiveness and associated biomarkers.
- The study included 70 elderly patients with various forms of myelodysplastic syndrome, assessing multiple factors like serum erythropoietin levels and the RED score to predict treatment response.
- Results showed nearly half (48%) of the patients had an erythroid response, with predictors of low response being higher RED scores and lower hepcidin:ferritin ratios.
Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.
View Article and Find Full Text PDFObjectives: To assess the reduction of transfusions rate in transfusion-dependent patients with low-risk myelodysplastic syndrome (MDS) with iron overload treated with deferasirox.
Methods: Prospective observational study. Primary endpoint was reduction in transfusion requirements (RTR) at 3 months, (assessed on 8-week period).